NSCLC: Update Bulletin [April 2016]
Gain new KOL insights on the latest events with the potential to shape the targeted treatment of Non-Small Cell Lung Cancer (NSCLC). Topics covered include opinions about the FDA advisory committee vote against approval of Clovis’s EGFR inhibitor rociletinib, the US FDA priority review granted for Roche’s PD-L1 inhibitor atezolizumab for the treatment of locally advanced or metastatic NSCLC expressing PD-L1, the EMA’s CHMP recommendation for approval of BMS’s Opdivo (nivolumab) for the treatment of locally advanced or metastatic NSCLC after prior chemotherapy, OSE Pharma’s Phase III trial of its OSE 2101 vaccine for the second- or third-line treatment of advanced HLA-A2 positive NSCLC, the US FDA and EU approval Boehringer Ingelheim's afatinib (Gilotrif /Giotrif) for the treatment of advanced squamous NSCLC that has progressed on or after platinum-based chemotherapy, and Ariad’s initiation of Phase III development of its ALK inhibitor brigatinib.
Please Note: Due to the brevity and/or nature of the content posted, there is no table of contents available for this report.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook